Transplantation & Immunosuppression


Immunosuppression (IS) is administered to kidney transplant recipients to prevent rejection episodes and loss of the renal allograft. Most centers rely on a triple IS after induction with either interleukin‑2 receptor antibodies or antithymocyte globulin. The most frequently used substances for maintenance IS are glucocorticoids, antimetabolites, mTOR inhibitors (mTORi), calcineurin inhibitors (CNI) and the costimulation blocker belatacept. Guidelines recommend a triple combination consisting of CNIs, antimetabolites and corticosteroids for the majority of patients. The long-term risk for malignancy in general is increased in solid organ recipients compared to the general population. Modification of IS may result in reduced risk for non-melanoma skin cancers but results in higher graft rejection rates and in the case of mTORi, deaths. In the case of posttransplantation lymphoproliferative disorders (PTLD) treatment options are reduction of IS, rituximab, chemotherapy, radiation therapy or a combination of these. The optimal protocol has not yet been established and depends on patient age and status, tumor load, laboratory findings, organ functions (heart, kidney, liver) and PTLD subtype. Posttransplantation diabetes mellitus is a frequent complication after kidney transplantation. Tacrolimus more than cyclosporine A.



 


    Related Conference of Transplantation & Immunosuppression

    August 28-29, 2025

    10th World Kidney Congress

    London, UK
    November 03-04, 2025

    29th European Nephrology Conference

    Rome, Italy
    December 10-11, 2025

    12th World Congress on Epidemiology & Public Health

    Amsterdam, Netherlands
    March 09-10, 2026

    17th Nephrology,Renal Medicine & Renal Care

    Dubai, UAE
    March 26-27, 2026

    22nd World Nephrology Conference

    Amsterdam, Netherlands
    June 29-30, 2026

    18th World Nephrology Summit

    Aix-en-Provence, France

    Transplantation & Immunosuppression Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in